Holen Sie sich die Stockscreener-App
10.47
4.48%
-0.47
Schlusskurs vom Vortag:
$10.94
Offen:
$10.78
24-Stunden-Volumen:
96,091
Relative Volume:
0.16
Marktkapitalisierung:
$568.24M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-6.6266
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-10.99%
1M Leistung:
+19.43%
6M Leistung:
+52.00%
1J Leistung:
+171.43%
1-Tages-Spanne:
$10.37
$10.94
1-Wochen-Bereich:
$10.37
$11.99
52-Wochen-Spanne:
$2.315
$12.19
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
10.50 | 592.06M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.46 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.12 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.53 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
890.30 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.51 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
How Fulcrum Therapeutics Inc. stock performs in stagflation2025 Dividend Review & AI Forecasted Entry and Exit Points - BỘ NỘI VỤ
Will Fulcrum Therapeutics Inc. stock benefit from AI adoptionSwing Trade & Stepwise Trade Signal Guides - moha.gov.vn
Contrasting Fulcrum Therapeutics (NASDAQ:FULC) and TG Therapeutics (NASDAQ:TGTX) - Defense World
Why Fulcrum Therapeutics Inc. stock is a must watch in 2025Weekly Stock Analysis & Real-Time Volume Trigger Notifications - BỘ NỘI VỤ
Fulcrum Therapeutics Inc (FULC) expanding its growth trajectory ahead - Setenews
Fulcrum Therapeutics (NASDAQ:FULC) Now Covered by Truist Financial - Defense World
Fulcrum Therapeutics stock price target raised to $18 from $12 at H.C. Wainwright - Investing.com Canada
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Truist Securities Initiates Buy Rating on Fulcrum Therapeutics (FULC) | FULC Stock News - GuruFocus
FULC Stock Boosted: HC Wainwright & Co. Raises Price Target to $ - GuruFocus
Truist Securities initiates coverage on Fulcrum Therapeutics stock with Buy rating - Investing.com UK
Insider Sell Alert: Robert Gould Sells 15,000 Shares of Fulcrum Therapeutics Inc (FULC) - GuruFocus
Fulcrum Therapeutics Director Sells 15,000 Shares - TradingView
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dir Gould Sells 15,000 ($165.5K) Of Fulcrum Therapeutics Inc [FULC] - TradingView
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
Will Fulcrum Therapeutics Inc. stock deliver consistent dividends2025 Winners & Losers & Long-Term Growth Plans - newser.com
How Fulcrum Therapeutics Inc. stock valuations compare to rivals2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
Will Fulcrum Therapeutics Inc. stock gain from strong economyRate Hike & Low Risk Entry Point Tips - newser.com
What date does Fulcrum Therapeutics's (FULC) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
How Fulcrum Therapeutics Inc. stock compares to growth peersEarnings Recap Report & Real-Time Volume Triggers - newser.com
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Year in Review & Stock Portfolio Risk Control - newser.com
Is Fulcrum Therapeutics Inc. stock attractive for passive investorsJuly 2025 Fed Impact & Smart Investment Allocation Tips - newser.com
Will Fulcrum Therapeutics Inc. stock beat EPS estimatesQuarterly Earnings Report & Expert Approved Momentum Trade Ideas - newser.com
This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily
Identifying reversal signals in Fulcrum Therapeutics Inc.Weekly Market Report & Verified Stock Trade Ideas - newser.com
Momentum divergence signals in Fulcrum Therapeutics Inc. chartTrade Risk Assessment & Expert Approved Momentum Trade Ideas - newser.com
Multi asset correlation models including Fulcrum Therapeutics Inc.Quarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Datanomix and Fulcrum Modernize Manufacturing Tech Stacks with Seamless ERP + Production Monitoring Integration - GlobeNewswire Inc.
How Fulcrum Therapeutics Inc. stock responds to policy changesQuarterly Performance Summary & Accurate Trade Setup Notifications - newser.com
Tick level data insight on Fulcrum Therapeutics Inc. volatilityBond Market & Daily Growth Stock Tips - newser.com
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):